First members Morris Rosenberg and Robert Lutz will support and advance the company's ADC development pipeline
Rosenberg has over 15 years in the ADC field, most notably as Vice President of Process Sciences at Seattle Genetics, whils Lutz spent 23 years with Immunogen, culminating in his role as Vice President of Translation Research and Development.
Lutz said: “The PermaLink conjugation technology provides a highly selective and safe alternative to the current maleimide chemistries, while reducing the significant risk associated with dedrugging of potent toxins and adverse events in the clinic.”
Rosenberg added: “Glythera has accessed an impressive range of novel approaches to on-market toxins which meets the industry’s current need for ADCs that can address difficult-to-treat solid tumours with highly potent toxin payloads.”
Glythera hopes to announce further key appointments to its SAB in due course.